Article Text

Download PDFPDF
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy
  1. Geetha Krishnamoorthy1,
  2. Aditya Kotecha2 and
  3. Jason Pimentel3
  1. 1 Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, Michigan, USA
  2. 2 Pulmonary/Critical Care, Henry Ford Hospital, Detroit, Michigan, USA
  3. 3 Pathology, Henry Ford Hospital, Detroit, Michigan
  1. Correspondence to Dr Aditya Kotecha, akotech1{at}


Erythrodermic psoriasis (EP) is the most serious type of psoriasis with high morbidity and mortality. First-line recommended therapies for EP, cyclosporine and infliximab have significant adverse effects. Cyclosporine increases the risk of hypertension, leucopenia, infections and renal failure. Infliximab increases the risk of reactivation of tuberculosis, hepatitis B and histoplasmosis, and increases risk for hepatitis, autoantibody formation, congestive heart failure, demyelinating disorders, pancytopenia, lymphoma and skin cancer. An effective drug with a much safer side effect profile will be of significant benefit in EP. The phosphodiesterase 4 inhibitor apremilast is U.S Food and Drug Administration (FDA) approved for plaque psoriasis and psoriatic arthritis. Adverse effects of apremilast reported are headache, nausea, diarrhoea, upper respiratory tract infection, potential for depression and weight loss. We report complete and long-standing resolution of EP with first-line apremilast monotherapy. Apremilast may be an effective option with comparatively minor side effects for EP.

  • dermatology
  • healthcare improvement and patient safety
  • medical management

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Patient consent for publication Obtained.

  • Contributors Patient care, literature review: GK and AK. Drafting manuscript: GK, AK and JP. Manuscript revision, intellectual revisions: GK and AK. Mentorship: GK. Final approval: GK, AK and JP.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.